Am J Blood Res 2011;1(1):22-33
Review Article
Therapeutic monoclonal antibodies for multiple myeloma: an update and
future perspectives
Jing Yang, Qing Yi
Department of Lymphoma/Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, The University of
Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Received April 25, 2011; accepted April, 2011; Epub April, 2011; published June 15, 2011
Abstract: Multiple myeloma (MM) still remains incurable in most of the patients. Despite of treatments with high-dose
chemotherapy, stem cell transplantation and other novel therapies, most patients will become refractory to the therapies and
relapse. Thus, it is urgent to develop new approaches for MM treatment. Currently, antibody-targeted therapy has been
extensively utilized in hematological malignancies, including MM. Several novel monoclonal antibodies (mAbs) against MM
have been generated and developed over the past several years. These mAbs aim to target not only tumor cells alone but also
tumor microenvironment, including interaction of tumor-bone marrow stromal cells and the components of bone marrow
milieu, such as cytokines or chemokines that support myeloma cell growth and survival. These include mAbs specific for
CD38, CS1, CD40, CD74, CD70, HM1.24, interleukin-6 and beta2-microglobulin (beta2M). We have shown that anti-beta2M
mAbs may be a potential antitumor agent for MM therapy due to their remarkable efficacy to induce myeloma cell apoptosis in
tumor cell lines and primary myeloma cells from patients in vitro and in established myeloma mouse models. In this article,
we will review advances in the development and mechanisms of MM-targeted mAbs and especially, anti-beta2M mAbs. We
will also discuss the potential application of the mAbs as therapeutic agents to treat MM. (AJBR1104001).
Keywords: Multiple myeloma, monoclonal antibodies, anti-2M mAbs, therapy
Full Text PDF
Address all correspondence to:
Qing Yi, MD, PhD
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard, Unit 0903
Houston, Texas 77030, USA.
Tel: 713 563 9065; Fax: 713 563 9241;
E-mail: qyi@mdanderson.org
Review Article
Therapeutic monoclonal antibodies for multiple myeloma: an update and
future perspectives
Jing Yang, Qing Yi
Department of Lymphoma/Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, The University of
Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Received April 25, 2011; accepted April, 2011; Epub April, 2011; published June 15, 2011
Abstract: Multiple myeloma (MM) still remains incurable in most of the patients. Despite of treatments with high-dose
chemotherapy, stem cell transplantation and other novel therapies, most patients will become refractory to the therapies and
relapse. Thus, it is urgent to develop new approaches for MM treatment. Currently, antibody-targeted therapy has been
extensively utilized in hematological malignancies, including MM. Several novel monoclonal antibodies (mAbs) against MM
have been generated and developed over the past several years. These mAbs aim to target not only tumor cells alone but also
tumor microenvironment, including interaction of tumor-bone marrow stromal cells and the components of bone marrow
milieu, such as cytokines or chemokines that support myeloma cell growth and survival. These include mAbs specific for
CD38, CS1, CD40, CD74, CD70, HM1.24, interleukin-6 and beta2-microglobulin (beta2M). We have shown that anti-beta2M
mAbs may be a potential antitumor agent for MM therapy due to their remarkable efficacy to induce myeloma cell apoptosis in
tumor cell lines and primary myeloma cells from patients in vitro and in established myeloma mouse models. In this article,
we will review advances in the development and mechanisms of MM-targeted mAbs and especially, anti-beta2M mAbs. We
will also discuss the potential application of the mAbs as therapeutic agents to treat MM. (AJBR1104001).
Keywords: Multiple myeloma, monoclonal antibodies, anti-2M mAbs, therapy
Full Text PDF
Address all correspondence to:
Qing Yi, MD, PhD
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard, Unit 0903
Houston, Texas 77030, USA.
Tel: 713 563 9065; Fax: 713 563 9241;
E-mail: qyi@mdanderson.org
| AJBR Copyright © 2011-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA |
 |  |  |  |  |  |  |